Moderna Inc., US60770K1034

Moderna stock falls after Rothschild Redburn downgrade

Published on 09/04/2026 at 13:26 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Moderna stock slipped after Rothschild Redburn cut its rating to Sell and raised its price target to USD 81 on September 3, 2026. The move followed strong melanoma vaccine trial data and a sharp rally.

Schwarzweißfoto von Forschern in Laborkitteln vor modernem Forschungsgebäude am Morgen
Moderna Inc. (US60770K1034) dokumentiert in Schwarzweiß-Reportage Forscher beim morgendlichen Betreten eines großen Biotech-Forschungscampus, Illustration mit AI erstellt.

Moderna Inc. (US60770K1034) stock fell after Rothschild & Co Redburn cut the rating to Sell and raised the price target to USD 81 from USD 40 on September 3, 2026. The shares were quoted at USD 146.24 after the initial drop, down 2.9 percent from the previous close, according to market coverage on September 4, 2026.

Sell call after a rally

According to GuruFocus, analyst Simon Baker shifted Moderna to Sell on September 3, 2026 and lifted the target by USD 41, or 102.5 percent, from USD 40 to USD 81. CNBC said the move followed a surge after Moderna and Merck reported positive Phase 3 INTerpath-001 data for the cancer vaccine candidate intismeran autogene.

Price and range

The stock was also trading 16.1 percent below its 52-week high of USD 174.38 from August 2026, while another market snapshot put the price at USD 150.81 on September 3, 2026 before the downgrade-driven pullback. GuruFocus also cited a market capitalization of about USD 60.2 billion.

Go deeper

Cancer vaccine data and the stock move

The latest catalyst is the Phase 3 melanoma readout and the market response around it.

Intismeran autogene

Moderna and Merck said the Phase 3 INTerpath-001 trial for intismeran autogene plus Keytruda reached its primary endpoint in high-risk melanoma, a result that helped drive the stock reaction. The market debate now centers on valuation, because the same readout that lifted the shares also triggered the downgrade and the USD 81 target.

Market snapshot

Moderna stock traded at USD 146.24 on September 4, 2026 after the downgrade-led pullback, with a prior snapshot at USD 150.81 on September 3, 2026 and a 52-week high of USD 174.38 in August 2026.

Moderna fact box

  • Company: Moderna Inc.
  • ISIN: US60770K1034
  • Ticker: MRNA
  • Trading venue: NASDAQ
  • Price (as of September 4, 2026): USD 146.24
  • Market capitalization: USD 60.2 billion (as of September 3, 2026)
  • Sector / Industry: Healthcare / Biotechnology
  • Index membership: S&P 500

Disclaimer...

en | US60770K1034 | MODERNA INC. | boerse | 70054209 | bgmi